GlassScriptPhysician profile
David Matthew Califf
NPI 1407537145
$4,157.55
in general payments reported to CMS, 2019-2025
18 companies · $1,782 in 2025
The $1,782 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $801 · 2024: $1,574 · 2025: $1,782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,156 · Education: $1.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,156.35 |
| Education | $1.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $736.59 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $617.78 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $364.67 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $356.80 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $265.46 | 2023-2024 | Azstarys, Azstarys |
| Bausch Health US, LLC | $258.44 | 2023-2025 | Aplenzin |
| Janssen Pharmaceuticals, INC | $238.13 | 2023-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $217.60 | 2024-2025 | Fanapt |
| Lundbeck LLC | $216.94 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $166.86 | 2023-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $137.15 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $133.92 | 2023-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $121.50 | 2023-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $94.37 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $64.98 | 2024 | Xelstrym, Secuado |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $62.99 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $52.89 | 2023-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $50.48 | 2023-2024 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Califf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.